Value Investor: CSL's growth injection

CSL investors should be pleased by the company's increased investment into research and development, which will solidify future earnings growth.

On October 27, CSL announced the $275 million acquisition of Novartis’ influenza vaccine business. The news excited investors, with CSL’s share price is up 5 per cent since the announcement. Their optimism is understandable: CSL’s past acquisitions have been very successful, achieving scale and operating leverage across the group.

{{content.question}}

{{ twilioFailed ? 'SMS Code Failed to Send…' : 'SMS Code Sent…' }}

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa
Mastercard

The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device


Register as a new member

(using a different email)

Related Articles